{"id":80853,"date":"2026-05-12T18:09:13","date_gmt":"2026-05-12T18:09:13","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/80853\/"},"modified":"2026-05-12T18:09:13","modified_gmt":"2026-05-12T18:09:13","slug":"novo-nordisk-presents-new-wegovy-data-showing-strong-weight-loss-fat-reduction-novo-nordisk-nysenvo","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/80853\/","title":{"rendered":"Novo Nordisk Presents New Wegovy Data Showing Strong Weight Loss, Fat Reduction – Novo Nordisk (NYSE:NVO)"},"content":{"rendered":"

The company also said a separate analysis showed most of the weight lost with Wegovy came from body fat<\/a>, while muscle function was preserved.<\/p>\n

\u2022\u00a0Novo Nordisk stock is trading near recent lows. What\u2019s next for NVO stock?<\/a><\/p>\n

Higher-Dose Wegovy Delivered Greater Weight Loss<\/p>\n

The STEP UP trial evaluated semaglutide 7.2 mg, semaglutide 2.4 mg, and placebo over 72 weeks in more than 1,400 adults with obesity who did not have Type 2 diabetes<\/a>.<\/p>\n

According to the data, participants taking the 7.2 mg dose lost an average of 21% of their body weight, equivalent to roughly 23 kilograms (~ 50 pounds) for the average participant who weighed 113 kilograms before treatment. <\/p>\n

Patients on the 2.4 mg dose lost about 17.5% of body weight, while placebo participants lost 2.4%.<\/p>\n

Novo Nordisk said<\/a> the higher dose demonstrated a safety and tolerability profile consistent with the 2.4 mg dose.<\/p>\n

STEP UP Analysis Examined Early Responders To Treatment<\/p>\n

A new STEP UP analysis also examined how quickly participants responded to treatment. Researchers defined “early responders” as individuals who lost at least 15% of their body weight within the first 24 weeks<\/a>.<\/p>\n

Among patients taking the 7.2 mg dose, 27% qualified as early responders, compared with 21% in the 2.4 mg group and 3% in the placebo group. Early responders in the 7.2 mg group ultimately lost 27.7% of body weight by week 72.<\/p>\n

Study Shows Majority Of Weight Loss Came From Fat<\/p>\n

Another sub-analysis involving 55 participants used MRI scans to evaluate body composition changes. The company said 84% of weight loss with semaglutide was tied to reductions in fat mass.<\/p>\n

Abdominal visceral fat declined by more than 30%, while muscle mass fell by about 10% from baseline. Researchers also reported preserved functional muscle strength, based on a 30-second sit-to-stand test<\/a>.<\/p>\n

NVO Price Action: Novo Nordisk shares were up 0.42% at $46.40 at the time of publication on Tuesday, according to Benzinga Pro. Over the past month, NVO has gained about 25% versus a 8.2% rise in the S&P 500 and is down roughly 10% year-to-date compared to the index\u2019s 6.9% gain.<\/p>\n

Photo: Piotr Swat \/ Shutterstock<\/p>\n

Market News and Data brought to you by Benzinga APIs<\/a><\/p>\n

\u00a9 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.<\/p>\n

To add Benzinga News as your preferred source on Google, click here<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"The company also said a separate analysis showed most of the weight lost with Wegovy came from body…\n","protected":false},"author":2,"featured_media":80854,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[2085,2094,2089,2087,2092,2088,5813,2093,2084,272,352,2096,2098,2099],"class_list":{"0":"post-80853","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-category-biotech","9":"tag-category-general","10":"tag-category-health-care","11":"tag-category-large-cap","12":"tag-category-movers","13":"tag-category-news","14":"tag-category-top-stories","15":"tag-category-trading-ideas","16":"tag-cms-wordpress","17":"tag-novo-nordisk","18":"tag-pageisbzpro-bz","19":"tag-symbol-nvo","20":"tag-tag-wegovy","21":"tag-tag-weight-loss"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116562949963653501","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/80853","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=80853"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/80853\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/80854"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=80853"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=80853"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=80853"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}